VYEPTI is designed for fast, powerful, and sustained response1,2

Immediate availability post-infusion2

Bioavailability post-infusion

100% bioavailability post 30-min IV administration2,3

Down arrow icon

Designed for rapid onset of activity2

Selective binding1

High selectivity for CGRP ligand

High selectivity for CGRP ligand1

Down arrow icon

Designed for no off-target activity1

Strong binding1

High affinity for CGRP ligand icon

High affinity for CGRP ligand1

Down arrow icon

Designed for sustained duration of action1

Relationship between pharmacodynamic activity and the mechanism(s) by which eptinezumab-jjmr exerts its clinical effects is unknown.3

Explore the MOA of VYEPTI

Learn how VYEPTI works and how it is specifically designed with high selectivity and affinity for the CGRP ligand1

MOA, mechanism of action.

VYEPTI IV is the only anti-CGRP that is 100% bioavailable—reaching Cmax in 30 minutes (at end of infusion).2,4

VYEPTI clinical trial data

Chronic and episodic migraine

VYEPTI IV treatment was evaluated for prevention of migraine in two phase 3 pivotal trials.2 See the changes from baseline in mean MMD (Months 1-3), Day 1 to Day 7, and more.

Dosing and administration

One 30-minute IV infusion every 3 months2

VYEPTI is the only anti-CGRP given as an IV treatment.2 See the administration details, including supplies, storage, and available doses.   

MMD, monthly migraine days.

You may also be interested in:

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. Garcia-Martinez LF, Raport CJ, Ojala EW, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther. 2020;374(1):93-103.
  2. Baker B, Schaeffler B, Beliveau M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8(2):e00567.
  3. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  4. Ong JJY, Wei DY, Goadsby PJ. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018:78(4):411-437.